Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Zalcitabine in AZT-Intolerant AIDS/ARC Patients
NCT00002265Phase 2Completed
- Sponsor
- Roche
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zalcitabine in human immunodeficiency virus infection (HIV), sponsored by Roche. Primary endpoints: Safety and Tolerability. Status: completed.
02
Drugs
zalcitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002265.